Retatrutide has emerged as a new medication in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By stimulating these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately r